Spots Global Cancer Trial Database for nk cell
Every month we try and update this database with for nk cell cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy | NCT01807611 | Leukemia Lymphoma | Total Lymphoid ... Fludarabine Cyclophosphamid... Thiotepa Melphalan HPC,A Infusion TC-NK Infusion G-CSF Mesna CliniMACS Mycophenolate m... | - 21 Years | St. Jude Children's Research Hospital | |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | NCT03019666 | Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt... | Nicotinamide Ex... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | NCT03019666 | Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt... | Nicotinamide Ex... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation | NCT05250362 | Hematologic Mal... | Allogeneic Hema... | 18 Years - 60 Years | Sichuan University | |
| Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours | NCT01337544 | Childhood Solid... | HAPLOIDENTICAL ... | 6 Months - 22 Years | Hospital Infantil Universitario Niño Jesús, Madrid, Spain | |
| Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy | NCT03941262 | Refractory Canc... Metastatic Canc... Recurrent Cance... Unresectable Ca... Solid Tumor, Ad... Advanced Cancer Advanced Solid ... | SNK01 Avelumab Pembrolizumab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours | NCT01337544 | Childhood Solid... | HAPLOIDENTICAL ... | 6 Months - 22 Years | Hospital Infantil Universitario Niño Jesús, Madrid, Spain | |
| Study of DF1001 in Patients With Advanced Solid Tumors | NCT04143711 | Solid Tumor, Ad... | DF1001 Nivolumab Nab paclitaxel Sacituzumab Gov... | 18 Years - | Dragonfly Therapeutics | |
| QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma | NCT02099539 | Relapsed or Ref... | ALT-803 | 18 Years - | Altor BioScience | |
| FT538 in Subjects With Advanced Hematologic Malignancies | NCT04614636 | Acute Myeloid L... AML, Adult Multiple Myelom... Myeloma | FT538 Cyclophosphamid... Fludarabine Daratumumab Elotuzumab | 18 Years - | Fate Therapeutics | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC | NCT05171309 | Hepatocellular ... | Apatinib Camrelizumab NK cell | 18 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma | NCT05909098 | NK Cell B-cell Lymphoma... B-cell Lymphoma... | autologous NK c... | 18 Years - 80 Years | Xiangyang No.1 People's Hospital | |
| FT538 in Subjects With Advanced Hematologic Malignancies | NCT04614636 | Acute Myeloid L... AML, Adult Multiple Myelom... Myeloma | FT538 Cyclophosphamid... Fludarabine Daratumumab Elotuzumab | 18 Years - | Fate Therapeutics | |
| Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation | NCT05250362 | Hematologic Mal... | Allogeneic Hema... | 18 Years - 60 Years | Sichuan University | |
| QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma | NCT02099539 | Relapsed or Ref... | ALT-803 | 18 Years - | Altor BioScience | |
| QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma | NCT02099539 | Relapsed or Ref... | ALT-803 | 18 Years - | Altor BioScience |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
